Business UpdateJun 1, 2026, 07:32 AM
Cognition Therapeutics CEO to Present DLB Psychosis Program Updates
AI Summary
Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will present at the 2026 Jefferies Global Healthcare Conference and the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit in June. Ms. Ricciardi will provide updates on the company's plans for a registration program in dementia with Lewy bodies (DLB) psychosis. The company's lead candidate, zervimesine (CT1812), is an investigational oral therapy that has shown promise in Phase 2 clinical trials for DLB and mild-to-moderate Alzheimer's disease.
Key Highlights
- Cognition Therapeutics CEO Lisa Ricciardi to present at two financial conferences in June.
- Presentations will provide updates on plans for a registration program in DLB psychosis.
- Jefferies Global Healthcare Conference presentation is on June 4, 2026, at 1:25 p.m. Eastern Time.
- H.C. Wainwright Neuro Perspectives Expert Summit presentation is on-demand from June 15, 2026, at 8:00 a.m. Eastern Time.
- The company's lead candidate, zervimesine (CT1812), showed strong efficacy signals in the Phase 2 SHIMMER study in DLB.
Price Impact
More from CGTX